Funding for this research was provided by:
NIHR School for Primary Care Research (206)
Received: 1 March 2020
Accepted: 18 May 2020
First Online: 11 June 2020
Compliance with ethical standards
: NQ was a member of the English NICE guideline development group on “Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer” (CG 164), he has received honorarium from AMGEN for talks on Familial Hypercholesterolaemia. SW is a member of the CPRD Independent Scientific Advisory Committee at the UK MHRA, has received honorarium as an advisor to AMGEN-EU scientific advisory board for data science. JFRR has consulted for AstraZenca, Bayer, Carrick Therapeutics & Cullinan Oncology. He also has provided expert testimony for AstraZeneca. He holds shares in Oncimmune Holdings, FaHRAS Ltd and Carrick Therapeutics. The remaining authors have no conflicts to disclose.
: The study was approved by East Midlands National Research Ethics Service (NRES) Committee (Reference 14/EM/0009).